Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation

This study is testing a drug called IBI351 — which targets a specific mutation in cancer cells called KRAS G12C — combined with chemotherapy in patients with advanced non-squamous non-small cell lung cancer. KRAS G12C is a genetic "on-switch" that drives cancer growth; IBI351 is designed to block it. **You may be eligible if...** - You have confirmed non-squamous non-small cell lung cancer with a KRAS G12C mutation - Your cancer is unresectable (cannot be surgically removed) or has spread - You have not received any prior systemic treatment for your advanced lung cancer - Your organ function is adequate **You may NOT be eligible if...** - You have had prior treatment targeting KRAS G12C - You have active brain metastases - You have had major stomach surgery or cannot swallow oral medications Talk to your doctor to see if this trial is right for you.